The Prescription Drug Price Relief Act of 2025 aims to significantly reduce the high cost of prescription drugs in the United States by eliminating monopolies that allow drug manufacturers to charge prices exceeding the median prices in other countries. The legislation introduces a systematic approach for identifying excessively priced drugs, with the Secretary of Health and Human Services tasked with reviewing brand name drugs annually against prices in Canada, the United Kingdom, Germany, France, and Japan.